NCT03114683View on ClinicalTrials.gov

Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 30, 2017

Primary Completion Date

September 12, 2019

Study Completion Date

November 30, 2019

Conditions

Relapsed/Refractory Classical Hodgkin's Lymphoma

Interventions

DRUG

PD1

IBI308 200mg/3 weeks

Trial Locations (1)

Unknown

Cancer hospital Chinese academy of Medical sciences, Beijing

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT03114683 - Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter